Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...

Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights ...

The S&P 500 ended down on Wednesday after a hotter-than-expected US inflation reading added to worries that the Federal ...

Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.

U.S. consumer prices increased in January by the most in nearly a year and a half. The surge offered a cautionary note to Trump's push for tariffs.

Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...

U.S. consumer prices increased in January by the most in nearly a year and a half, reinforcing the Fed’s message that it was ...